Although fibronectin did not lead to a significant survival prolongation in BCR-ABL1+ B-ALL or MLL-AF9+ AML, it is likely that this may have been due to suboptimal dosing and timing of the administration of fibronectin, whose high purchasing costs were prohibitive of further exploration in this study. Here, FN1 is linked to acute lymphoblastic leukemia.